Executive Briefing
Week ending September 6, 2026
1. Headline
22 cross-response inconsistencies this week, down 10 week over week, but contraindication mentions rose to 34 (+6) and remain a material risk. The main exposure is uneven safety coverage: some answer instances include boxed warnings, pancreatitis, kidney risk, or hypoglycemia while others omit them—creating a variable patient and HCP experience.
2. This week at a glance
| Metric | This week | Change vs. last week |
|---|---|---|
| Distinct questions / responses | 12 / 81 | -8 / -39 |
| Inconsistency flags | 22 | -10 |
| Top competitor mentions | Wegovy 25; Trulicity 7; Mounjaro 7 | -19; -15; -16 |
| Top safety/regulatory themes | Contraindication 34; pancreatitis 27; hypoglycemia 23 | +6; -9; -6 |
Attribution is reported as response variants; named-model comparison is not used because reliable model-attribution status was not provided.
3. Trajectory
Overall consistency is improving from the August peak: inconsistency flags rose from 16 on July 12 to 39 on August 9, then declined to 22 this week. The clearest inflection was the August 9 high point, followed by improvement across the next four weeks. However, lower monitoring volume also contributes: responses fell from 120 last week to 81 this week, so the improvement should not be treated as fully resolved.
Competitor visibility is also down with volume. Wegovy remains the dominant named competitor, appearing in 25 answers, but mentions have fallen from 44 last week and from a high of 47 on July 26. Trulicity and Mounjaro each appear seven times, down substantially week over week.
Safety themes are not uniformly improving. Contraindication mentions increased to 34, while kidney-risk and pregnancy/lactation mentions are also above last week (18, +2 and 15, +2).
4. Where the risk actually is
- Label-comparison question: Five of seven answer instances omitted at least one major safety topic, including the boxed warning, contraindications, pancreatitis, thyroid tumors, kidney risk, or hypoglycemia. A user seeking compliant comparative claims may receive a materially incomplete safety answer.
- Kidney-disease question: Six of seven instances omitted contraindication context, and five omitted hypoglycemia. The core renal guidance is generally consistent, but important risk framing is not.
- Warnings/contraindications questions: Safety coverage varies across answer instances. This is especially consequential for thyroid C-cell tumor/MEN2 warnings, pancreatitis, and serious allergic reactions.
5. Recommended actions
- Medical Affairs + content/SEO: Create authoritative, retrieval-friendly FAQ modules for boxed warning, contraindications, pancreatitis, kidney monitoring, pregnancy, and hypoglycemia. Target the omissions in the label-comparison and kidney questions.
- Medical Affairs/PV: Review and approve a standardized safety-response framework, including “do not use” versus “use with caution” distinctions. Contraindication mentions rose +6 this week.
- Content governance: Add an answer-quality test set requiring consistent inclusion of high-priority warnings across dosing, missed-dose, and comparative questions; specifically resolve the observed 48-hour versus five-day missed-dose variation.
- Marketing/legal review: Tighten comparative-claim guardrails for Wegovy, Trulicity, and Mounjaro; competitor mentions remain frequent despite declining volume.